pmed.1003926.s003.pdf (575.95 kB)
S1 Table -
journal contribution
posted on 2022-02-22, 19:01 authored by William N. Whiteley, Samantha Ip, Jennifer A. Cooper, Thomas Bolton, Spencer Keene, Venexia Walker, Rachel Denholm, Ashley Akbari, Efosa Omigie, Sam Hollings, Emanuele Di Angelantonio, Spiros Denaxas, Angela Wood, Jonathan A. C. Sterne, Cathie SudlowEstimates for (a) age-stratified risk of venous and arterial events during follow-up; (b) age-stratified incidence of events pre- and post-first ChAdOx1-S; (c) age-stratified incidence of events pre- and post-first BNT162b2; (d) age- and sex-stratified HR of events 1–28 and >28 days post-ChAdOx1-S vaccine; and (e) age- and sex-stratified HR of events 1–28 and >28 days post-ChAdOx1-S vaccine BNT162b2 vaccine. HR, hazard ratio.
(PDF)
History
Usage metrics
Keywords
positive predictive valuecoded healthcare dataalso prespecified adjustment18 march 2021deep vein thrombosiscoronavirus disease 2019lipid lowering medicationbased cohort studyapproximately 21 million46 %) adultsci ): 1388 december 202046 million adultsintracranial venous thrombosisestimated incidence ratescrude incidence ratesxlink "> ratesxlink "> thromboses79 %) white5 %) blackfirst vaccination dose28 days postpopulation cohort study1 %) asian≥ 70 yearsengland pvenous thrombotic eventseither vaccine compared3 per millionthrombocytopenic outcomes 119 vaccines chadox1xlink ">either vaccine5 millionvenous thrombosisthrombotic eventsthrombocytopenic events84 %)51 %)per 100first vaccinationcoronavirus infectionblack britishasian britishadults livingadults aged28 daysvenous thrombosesvenous eventsvaccine chadox1antiplatelet medicationanticoagulant medication7 million6 million39 million36 million23 million2 %)major venousarterial thrombosesunusual locationssmall comparedpulmonary embolismprimary reasonprecise estimatespopulation levelperformed separatelyobserved increasesmyocardial infarctionmeasure outcomemay leadmain limitationslevel risksidentify exposureshospital admissionhazard ratiosgenerally lowerdifferent typesconfidence interval70 years40 years307 );291 ).269 );253 );237 );19 morbidity000 person 8805